A Phase 2/3 interventional study of Remdesivir in COVID-19, sponsored by Gilead Sciences. Completed at 32 sites in 4 countries. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2024-02-06.
Sponsored by Gilead Sciences · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies testing remdesivir in COVID-19 — 6 open to participants now, 9 under way, 3 of them phase 3. remdesivir · COVID-19.
Among the 40 studies testing remdesivir in COVID-19, this one is the 36th largest by enrollment, is one of 27 that started in 2020, is one of 5 in phase 2/3, and was the 12th registered.
7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.
Browse COVID-19 studies →6 of the 40 studies testing remdesivir in COVID-19 are open now, in 12 countries. Recruiting first, the newest first:
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia · Sites in Spain
Ages 18+
Pfizer · Sites in United States, Argentina, Belgium and 15 more countries
Ages 18+
ANRS, Emerging Infectious Diseases · Sites in France, Italy, Norway
Ages 16+
University of Oxford · Sites in Brazil, Laos, Nepal and 2 more countries
Ages 18–60
Lebanese University · Sites in Lebanon
Ages 18+
By country, each count listing its studies:
remdesivir: first FDA approval 2020 (VEKLURY), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: Up to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 12 · Phase 3 22 · Phase 4 5
First in 2016; this study’s year is marked. 27 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 59 is below the median of 102 across 4,366 interventional studies indexed under COVID-19.
Median enrollment 283 across the 40 interventional studies. Of the 20 that completed or were terminated, 10 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 40 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
10 studies in COVID-19 by Gilead Sciences: none open now, none under way, none of them phase 3. Of 9 finished, 9 (100%) have results posted.
Among the 10 studies in COVID-19 by Gilead Sciences, this one is one of 5 that started in 2020, is one of 2 in phase 2/3, and was the 4th registered.
Gilead Sciences’s COVID-19 studies by the year they started, since 2020.
4 of the studies testing remdesivir in COVID-19 that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT07197164Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la CienciaSafety and Effectiveness of a Remdesivir Treatment to Prevent Severe COVID-19 in Kidney Transplant Patients | 2026-12-30 |
| NCT05587894ANRS, Emerging Infectious DiseasesOPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial | 2026-12-31 |
| NCT05041907University of OxfordFinding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) | 2027-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 40 studies testing remdesivir in COVID-19, from their registry updates:
Among Gilead Sciences’s 10 in COVID-19:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goals of this clinical study are to learn more about the study drug, remdesivir, and how safe it is in participants less than 18 years old with coronavirus disease 2019 (COVID-19).
Pediatric participants will be enrolled as follows:
Pediatric participants ≥ 28 days to \< 18 years old:
Term neonatal participants 0 days to \< 28 days old:
Preterm neonates and infants 0 days to \< 56 days old:
Key Inclusion Criteria:
Aged \< 18 years of age who meet one of the following weight criteria (where permitted according to local law and approved nationally and by relevant institutional review board (IRB) or independent ethics committee (IEC)).
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive RDV 200 mg, intravenous (IV) infusion on Day 1 followed by RDV 100 mg, IV infusion, daily, up to 10 days.
Drug: Remdesivir
Participants will receive RDV 5 mg/kg, IV infusion on Day 1 followed by RDV 2.5 mg/kg mg, IV infusion, daily, up to 10 days.
Drug: Remdesivir
Participants will receive RDV 5 mg/kg, IV infusion on Day 1 followed by RDV 2.5 mg/kg mg, IV infusion, daily, up to 10 days.
Drug: Remdesivir
Participants will receive RDV 5 mg/kg, IV infusion on Day 1 followed by RDV 2.5 mg/kg mg, IV infusion, daily, up to 10 days.
Drug: Remdesivir
Participants will receive RDV 5 mg/kg, IV infusion on Day 1 followed by RDV 2.5 mg/kg mg, IV infusion, daily, up to 10 days.
Drug: Remdesivir
Participants will receive RDV 2.5 mg/kg, IV infusion on Day 1 followed by RDV 1.25 mg/kg mg, IV, daily, up to 10 days.
Drug: Remdesivir
Participants will receive RDV 2.5 mg/kg, IV infusion on Day 1 followed by RDV 1.25 mg/kg mg, IV, daily, up to 10 days.
Drug: Remdesivir
Participants will receive RDV 200 mg, IV infusion on Day 1 followed by RDV 100 mg, IV infusion daily up to 10 days.
Drug: Remdesivir
Administered as an intravenous infusion
Also known as: GS-5734™, Veklury®
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)
TEAEs were defined as any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug and/or any AEs leading to premature discontinuation of study drug.
Time frame: From first dose date (Day 1) up to follow-up assessment (maximum duration: 30 days)
Percentage of Participants With Treatment-Emergent Graded Laboratory Abnormalities
Treatment-emergent graded laboratory abnormalities were defined as values that increase at least 1 toxicity grade from baseline at any time post baseline up to and including the date of last dose of study drug plus 30 days. The laboratory abnormalities were graded using division of allergy and infectious diseases (DAIDS) scale. DAIDS scale is used to grade the severity of adult and pediatric unwanted medical events. Grade 1: mild event, Grade 2: moderate event, Grade: serious event, Grade 4: potentially life-threatening event.
Time frame: From first dose date (Day 1) up to follow-up assessment (maximum duration: 30 days)
Pharmacokinetic (PK) Parameter: Cmax of Remdesivir and Its Metabolites GS-704277 and GS-441524 at Steady State
Cmax is defined as maximum plasma concentration of drug. Plasma concentrations were drawn as follows: (1) for Cohorts 1-4 and 8 on Day 2 and Day 3 with Day 5 as optional; (2) for Cohorts 5-7 on Day 2 or Day 3.
Time frame: Day 2: end of infusion and 4 hours post end of infusion, Day 3: pre-infusion and 2 hours post end of infusion, and Day 5: middle of infusion and 6 hours post end of infusion; infusion duration: 30 minutes to 2 hours
PK Parameter: AUCtau of Remdesivir and Its Metabolites GS-704277 and GS-441524 at Steady State
AUCtau is defined as area under the concentration versus time curve over the dosing interval. Plasma concentrations were drawn as follows: (1) for Cohorts 1-4 and 8 on Day 2 and Day 3 with Day 5 as optional; (2) for Cohorts 5-7 on Day 2 or Day 3.
Time frame: Day 2: end of infusion and 4 hours post end of infusion, Day 3: pre-infusion and 2 hours post end of infusion, and Day 5: middle of infusion and 6 hours post end of infusion; infusion duration: 30 minutes to 2 hours
Percentage of Participants With Clinical Improvement on a 7-point Ordinal Scale Score
Clinical improvement was defined as ≥ 1-point and ≥ 2-point improvement from Baseline clinical status or recovery or discharged alive on 7-point ordinal scale. Recovery was defined as an improvement from a Baseline score of 2 - 5 to a score of 6 or 7 or an improvement from a Baseline score of 6 to 7 on the ordinal scale. The ordinal scale was used for the assessment of the clinical status at a given day using a 7-point ordinal scale with an increasing score indicating improvement. Scale: 1=Death, 2=Hospitalized, on invasive mechanical ventilation or ECMO, 3=Hospitalized, on non-invasive ventilation or high flow oxygen devices, 4=Hospitalized, requiring low flow supplemental oxygen, 5=Hospitalized, not requiring supplemental oxygen-requiring ongoing medical care COVID-19 related or otherwise), 6=Hospitalized, not requiring supplemental oxygen-no longer required ongoing medical care (other than RDV administration), 7=Not hospitalized. The 95% CI was based on the Clopper-Pearson method.
Time frame: Day 10
Time (Days) to Discharge From Hospital
Time to discharge was the duration from the first dose date to getting discharged from the hospital.
Time frame: From first dose date (Day 1) up to follow-up assessment (maximum duration: 30 days)
Number of Participants With Change From Baseline in Oxygenation Use
Oxygen support status was derived from the 7-point ordinal scale score, 1 = death; 2 = invasive mechanical ventilation; 3 = high flow oxygen; 4 = low flow oxygen; 5 or 6 = room air; 7 = discharge. Change from Baseline for participants with oxygenation use status as '3=High Flow Oxygen', '4=Low Flow Oxygen' and '5=Room Air' at Baseline.
Time frame: Day 10
Number of Participants With Change From Baseline in the Use of Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO)
Mechanical ventilation status was derived from the 7-point ordinal scale score, 1 = death; 2 = invasive mechanical ventilation; 3 = high flow oxygen; 4 = low flow oxygen; 5 or 6 = room air; 7 = discharge.
Time frame: Day 10
Days to First Confirmed Negative Polymerase Chain Reaction (PCR) Result
Confirmed negative PCR is defined by as 2 consecutive negative PCR results or negative result at the last available sample for participants who completed or discontinued from the study. The assessment were done for the samples: nasal/oropharyngeal (OP), nasopharyngeal (NP)/oropharyngeal (OP), endotracheal (ET) aspirates, and rectal/fecal swabs.
Time frame: From first dose date (Day 1) up to follow-up assessment (maximum duration: 30 days)
Change From Baseline in Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Viral Load Up to Day 10 or Up to the First Confirmed Negative PCR Result
Change from baseline in SARS-CoV-2 viral load up to Day 10 or up to the first negative PCR result with confirmation (whichever comes first) were reported. The assessment were done for the samples: nasal/oropharyngeal (OP) samples, nasopharyngeal (NP)/OP samples, endotracheal (ET) aspirates, and rectal/fecal swabs.
Time frame: Baseline, Day 10, and Day of Discharge (Day 10 or before)
Bilirubin Concentrations in < 14-day-old Participants
Time frame: From first dose date (Day 1) up to follow-up assessment (maximum duration: 30 days)
Percentage of Participants With Clinical Improvement Based on Scoring Using the Pediatric Early Warning Score (PEWS) Improvement Scale
The PEWS was measured by 3 components, where 1= behavior, 2= perfusion assessed by capillary refill and heart rate, and 3= respiratory status assessed by respiratory rate, effort, and oxygen requirement. The score ranged between 0 to 9 point, with higher score representing the highest severity level. A negative change from baseline value indicated an improvement. Data are reported for participants with a PEWS behavior score ≥ 2 at baseline, and a ≥ 2-point improvement (indicated by a decrease) in PEWS behavior score by Day 10, participants with a PEWS behavior score ≥ 1 at baseline, with ≥ 1-point improvement in PEWS behavior score by Day 10 and participants who recovered in PEWS behavior, defined as a Baseline score of 1 through 3 improved to a score of 0.
Time frame: Day 10
Plasma Concentrations of Sulfobutylether β-cyclodextrin Sodium (SBECD)
Plasma concentrations were drawn as follows: (1) for Cohorts 1-4 and 8 on Day 2 and Day 3, with Day 5 as optional; (2) for Cohorts 5-7 on Day 2 or Day 3.
Time frame: Day 2: end of infusion and 4 hours post end of infusion, Day 3: pre-infusion and 2 hours post end of infusion, and Day 5: middle of infusion and 6 hours post end of infusion; infusion duration: 30 minutes to 2 hours
Percentage of Participants With Concomitant Use of Medications Other Than RDV for Treatment of COVID-19
Participants who received at least one concomitant non-study COVID-19 medication from the first day of RDV treatment through the 30-day Follow-up visit or early withdrawal are reported.
Time frame: first dose date (Day 1) up to follow-up assessment (maximum duration: 30 days)
Participants were enrolled at study sites in Italy, Spain, the United Kingdom, and the United States.
| Milestone | Remdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kg | RDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kg | RDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kg | RDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kg | RDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kg | RDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kg | RDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kg | RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg |
|---|---|---|---|---|---|---|---|---|
| Started | 12 | 12 | 12 | 12 | 4 | 1 | 1 | 5 |
| Completed | 11 | 11 | 11 | 9 | 3 | 1 | 1 | 4 |
| Not completed | 1 | 1 | 1 | 3 | 1 | 0 | 0 | 1 |
| Withdrew: Withdrew consent | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Enrolled but never treated | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
TEAEs were defined as any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug and/or any AEs leading to premature discontinuation of study drug.
| percentage of participants | Remdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kg | RDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kg | RDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kg | RDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kg | RDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kg | RDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kg | RDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kg | RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) | 91.7 | 58.3 | 75.0 | 58.3 | 66.7 | — | — | 80.0 |
Treatment-emergent graded laboratory abnormalities were defined as values that increase at least 1 toxicity grade from baseline at any time post baseline up to and including the date of last dose of study drug plus 30 days. The laboratory abnormalities were graded using division of allergy and infectious diseases (DAIDS) scale. DAIDS scale is used to grade the severity of adult and pediatric unwanted medical events. Grade 1: mild event, Grade 2: moderate event, Grade: serious event, Grade 4: potentially life-threatening event.
| percentage of participants | Remdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kg | RDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kg | RDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kg | RDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kg | RDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kg | RDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kg | RDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kg | RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg |
|---|---|---|---|---|---|---|---|---|
| Any grade | 100 | 83.3 | 91.7 | 90.9 | 100 | — | — | 80 |
| Grade 3 or 4 | 75 | 16.7 | 41.7 | 36.4 | 100 | — | — | 60 |
Cmax is defined as maximum plasma concentration of drug. Plasma concentrations were drawn as follows: (1) for Cohorts 1-4 and 8 on Day 2 and Day 3 with Day 5 as optional; (2) for Cohorts 5-7 on Day 2 or Day 3.
| ng/mL | Remdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kg | RDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kg | RDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kg | RDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kg | RDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kg | RDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kg | RDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kg | RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg |
|---|---|---|---|---|---|---|---|---|
| Remdesivir | 4108.7 ± 1365.15 | 6003.5 ± 1879.86 | 5980.1 ± 2284.08 | 5192.9 ± 2066.65 | 4829.0 ± 956.16 | — | — | 4235.7 ± 1790.53 |
| GS-704277 | 360.6 ± 208.11 | 469.0 ± 239.72 | 484.8 ± 244.07 | 407.8 ± 132.45 | 466.0 ± 110.87 | — | — | 297.9 ± 160.18 |
| GS-441524 | 276.4 ± 327.14 | 210.5 ± 121.02 | 186.5 ± 103.09 | 209.8 ± 49.73 | 371.8 ± 151.10 | — | — | 230.4 ± 255.03 |
AUCtau is defined as area under the concentration versus time curve over the dosing interval. Plasma concentrations were drawn as follows: (1) for Cohorts 1-4 and 8 on Day 2 and Day 3 with Day 5 as optional; (2) for Cohorts 5-7 on Day 2 or Day 3.
| h*ng/mL | Remdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kg | RDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kg | RDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kg | RDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kg | RDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kg | RDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kg | RDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kg | RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg |
|---|---|---|---|---|---|---|---|---|
| Remdesivir | 2630.1 ± 923.85 | 3937.9 ± 1981.40 | 6752.1 ± 10911.98 | 3625.7 ± 3361.19 | 2650.3 ± 587.77 | — | — | 2519.6 ± 1235.49 |
| GS-704277 | 1222.9 ± 1348.12 | 860.3 ± 512.58 | 876.0 ± 720.39 | 776.0 ± 485.18 | 1049.0 ± 253.73 | — | — | 671.4 ± 553.30 |
| GS-441524 | 5486.2 ± 7599.27 | 3016.1 ± 2425.78 | 2751.8 ± 1868.93 | 2969.1 ± 940.73 | 6899.3 ± 3910.28 | — | — | 4336.8 ± 5692.30 |
Clinical improvement was defined as ≥ 1-point and ≥ 2-point improvement from Baseline clinical status or recovery or discharged alive on 7-point ordinal scale. Recovery was defined as an improvement from a Baseline score of 2 - 5 to a score of 6 or 7 or an improvement from a Baseline score of 6 to 7 on the ordinal scale. The ordinal scale was used for the assessment of the clinical status at a given day using a 7-point ordinal scale with an increasing score indicating improvement. Scale: 1=Death, 2=Hospitalized, on invasive mechanical ventilation or ECMO, 3=Hospitalized, on non-invasive ventilation or high flow oxygen devices, 4=Hospitalized, requiring low flow supplemental oxygen, 5=Hospitalized, not requiring supplemental oxygen-requiring ongoing medical care COVID-19 related or otherwise), 6=Hospitalized, not requiring supplemental oxygen-no longer required ongoing medical care (other than RDV administration), 7=Not hospitalized. The 95% CI was based on the Clopper-Pearson method.
| percentage of participants | Remdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kg | RDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kg | RDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kg | RDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kg | RDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kg | RDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kg | RDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kg | RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg |
|---|---|---|---|---|---|---|---|---|
| ≥ 1-point Improvement from Baseline | 50.0 (21.1 to 78.9) | 91.7 (61.5 to 99.8) | 100.0 (73.5 to 100.0) | 58.3 (27.7 to 84.8) | 33.3 (0.8 to 90.6) | — | — | 80.0 (28.4 to 99.5) |
| ≥ 2-point Improvement from Baseline | 41.7 (15.2 to 72.3) | 91.7 (61.5 to 99.8) | 100.0 (73.5 to 100.0) | 54.5 (23.4 to 83.3) | 33.3 (0.8 to 90.6) | — | — | 80.0 (28.4 to 99.5) |
| Recovery | 25.0 (5.5 to 57.2) | 75.0 (42.8 to 94.5) | 91.7 (61.5 to 99.8) | 41.7 (15.2 to 72.3) | 33.3 (0.8 to 90.6) | — | — | 80.0 (28.4 to 99.5) |
Time to discharge was the duration from the first dose date to getting discharged from the hospital.
| days | Remdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kg | RDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kg | RDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kg | RDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kg | RDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kg | RDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kg | RDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kg | RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg |
|---|---|---|---|---|---|---|---|---|
| Time (Days) to Discharge From Hospital | 12 (8 to 24) | 7 (5 to 9) | 5 (4 to 9) | 7 (4 to 19) | NA (9 to NA) | — | — | 10 (4 to 18) |
Oxygen support status was derived from the 7-point ordinal scale score, 1 = death; 2 = invasive mechanical ventilation; 3 = high flow oxygen; 4 = low flow oxygen; 5 or 6 = room air; 7 = discharge. Change from Baseline for participants with oxygenation use status as '3=High Flow Oxygen', '4=Low Flow Oxygen' and '5=Room Air' at Baseline.
| Participants | Remdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kg | RDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kg | RDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kg | RDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kg | RDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kg | RDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kg | RDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kg | RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg |
|---|---|---|---|---|---|---|---|---|
| High flow oxygen (Baseline) — Death (Day 10) | 0 | 0 | 0 | 0 | 0 | — | — | 0 |
| High flow oxygen (Baseline) — IMV (Day 10) | 2 | 0 | 0 | 0 | 0 | — | — | 1 |
| High flow oxygen (Baseline) — High Flow oxygen (Day 10) | 1 | 0 | 0 | 0 | 0 | — | — | 0 |
| High flow oxygen (Baseline) — Low Flow oxygen (Day 10) | 0 | 0 | 0 | 0 | 0 | — | — | 0 |
| High flow oxygen (Baseline) — Room Air (Day 10) | 2 | 0 | 0 | 0 | 0 | — | — | 0 |
| High flow oxygen (Baseline) — Discharge (Day 10) | 1 | 4 | 3 | 2 | 1 | — | — | 1 |
| High flow oxygen (Baseline) — Missing (Day 10) | 0 | 0 | 0 | 1 | 0 | — | — | 0 |
| Low Flow Oxygen (Baseline) — Death (Day 10) | 0 | 0 | 0 | 0 | 0 | — | — | 0 |
| Low Flow Oxygen (Baseline) — IMV (Day 10) | 0 | 0 | 0 | 0 | 0 | — | — | 0 |
| Low Flow Oxygen (Baseline) — High Flow oxygen (Day 10) | 0 | 0 | 0 | 0 | 0 | — | — | 0 |
| Low Flow Oxygen (Baseline) — Low Flow oxygen (Day 10) | 0 | 0 | 0 | 1 | 0 | — | — | 0 |
| Low Flow Oxygen (Baseline) — Room Air (Day 10) | 1 | 0 | 0 | 0 | 0 | — | — | 1 |
| Low Flow Oxygen (Baseline) — Discharge (Day 10) | 1 | 3 | 0 | 2 | 0 | — | — | 1 |
| Low Flow Oxygen (Baseline) — Missing (Day 10) | 0 | 0 | 0 | 0 | 0 | — | — | 0 |
| Room Air (Baseline) — Death (Day 10) | 0 | 0 | 0 | 0 | 0 | — | — | 0 |
| Room Air (Baseline) — IMV (Day 10) | 0 | 0 | 0 | 0 | 0 | — | — | 0 |
| Room Air (Baseline) — High Flow oxygen (Day 10) | 0 | 0 | 0 | 0 | 0 | — | — | 0 |
| Room Air (Baseline) — Low Flow oxygen (Day 10) | 0 | 0 | 0 | 0 | 0 | — | — | 0 |
| Room Air (Baseline) — Room Air (Day 10) | 2 | 0 | 0 | 0 | 0 | — | — | 0 |
| Room Air (Baseline) — Discharge (Day 10) | 1 | 2 | 6 | 1 | 0 | — | — | 1 |
| Room Air (Baseline) — Missing (Day 10) | 0 | 0 | 0 | 0 | 0 | — | — | 0 |
Mechanical ventilation status was derived from the 7-point ordinal scale score, 1 = death; 2 = invasive mechanical ventilation; 3 = high flow oxygen; 4 = low flow oxygen; 5 or 6 = room air; 7 = discharge.
| Participants | Remdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kg | RDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kg | RDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kg | RDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kg | RDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kg | RDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kg | RDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kg | RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg |
|---|---|---|---|---|---|---|---|---|
| Death | 0 | 0 | 0 | 0 | 0 | — | — | — |
| Invasive Mechanical ventilation | 1 | 1 | 0 | 2 | 2 | — | — | — |
| High Flow Oxygen | 0 | 0 | 0 | 0 | 0 | — | — | — |
| Low Flow Oxygen | 0 | 1 | 0 | 0 | 0 | — | — | — |
| Room Air | 0 | 0 | 1 | 2 | 0 | — | — | — |
| Discharge | 0 | 0 | 2 | 0 | 0 | — | — | — |
| Missing | 0 | 1 | 0 | 1 | 0 | — | — | — |
Confirmed negative PCR is defined by as 2 consecutive negative PCR results or negative result at the last available sample for participants who completed or discontinued from the study. The assessment were done for the samples: nasal/oropharyngeal (OP), nasopharyngeal (NP)/oropharyngeal (OP), endotracheal (ET) aspirates, and rectal/fecal swabs.
| days | Remdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kg | RDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kg | RDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kg | RDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kg | RDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kg | RDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kg | RDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kg | RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg |
|---|---|---|---|---|---|---|---|---|
| Nasal/OP Samples | NA (5 to NA) | 5 (3 to NA) | 7 (5 to NA) | NA (4 to NA) | 10 (10 to 10) | — | — | NA (NA to NA) |
| NP/OP Samples | NA (NA to NA) | NA (7 to NA) | NA (5 to NA) | NA (10 to NA) | NA (NA to NA) | — | — | NA (NA to NA) |
| ET aspirates | NA (NA to NA) | NA (3 to NA) | NA (NA to NA) | NA (3 to NA) | NA (NA to NA) | — | — | — |
| Rectal/Faecal samples | 5 (3 to 10) | 3 (3 to 5) | 5 (3 to NA) | 7 (5 to NA) | 3 (3 to 5) | — | — | 4 (3 to 7) |
Change from baseline in SARS-CoV-2 viral load up to Day 10 or up to the first negative PCR result with confirmation (whichever comes first) were reported. The assessment were done for the samples: nasal/oropharyngeal (OP) samples, nasopharyngeal (NP)/OP samples, endotracheal (ET) aspirates, and rectal/fecal swabs.
| log10 copies per mL | Remdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kg | RDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kg | RDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kg | RDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kg | RDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kg | RDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kg | RDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kg | RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg |
|---|---|---|---|---|---|---|---|---|
| Nasal/OP Samples, Change at Day 10 | -3.01 ± NA | — | 0 ± 0 | — | -2.36 ± NA | — | — | -1.76 ± NA |
| Nasal/OP Samples, Change at Discharge | — | -4.65 ± NA | — | -1.56 ± 1.228 | — | — | — | — |
| NP/OP Samples, Change at Day 10 | — | -2.17 ± 2.197 | — | -2.60 ± 1.283 | -3.28 ± 0.183 | — | — | 0.46 ± NA |
| NP/OP Samples, Change at Discharge | -2.86 ± NA | -3.72 ± NA | -0.87 ± 1.391 | 1.42 ± NA | — | — | — | -0.05 ± 1.184 |
| ET aspirates, Change at Day 10 | — | -5.94 ± NA | — | — | -1.92 ± NA | — | — | — |
| Rectal or Fecal Swabs, Change at Day 10 | 0.38 ± NA | -0.39 ± NA | — | -1.87 ± NA | — | — | — | 1.38 ± NA |
| Rectal or Fecal Swabs, Change at Discharge | — | 1.12 ± NA | -0.09 ± 1.999 | -1.47 ± 0.479 | — | — | — | 0 ± 0 |
No measurements were reported for this outcome.
The PEWS was measured by 3 components, where 1= behavior, 2= perfusion assessed by capillary refill and heart rate, and 3= respiratory status assessed by respiratory rate, effort, and oxygen requirement. The score ranged between 0 to 9 point, with higher score representing the highest severity level. A negative change from baseline value indicated an improvement. Data are reported for participants with a PEWS behavior score ≥ 2 at baseline, and a ≥ 2-point improvement (indicated by a decrease) in PEWS behavior score by Day 10, participants with a PEWS behavior score ≥ 1 at baseline, with ≥ 1-point improvement in PEWS behavior score by Day 10 and participants who recovered in PEWS behavior, defined as a Baseline score of 1 through 3 improved to a score of 0.
| percentage of participants | Remdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kg | RDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kg | RDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kg | RDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kg | RDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kg | RDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kg | RDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kg | RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg |
|---|---|---|---|---|---|---|---|---|
| ≥ 2-point Improvement from Baseline- Respiratory | 33.3 (4.3 to 77.7) | 83.3 (35.9 to 99.6) | 75.0 (19.4 to 99.4) | 42.9 (9.9 to 81.6) | 0 (0 to 84.2) | — | — | 66.7 (9.4 to 99.2) |
| ≥ 1-point Improvement from Baseline- Respiratory | 50.0 (15.7 to 84.3) | 81.8 (48.2 to 97.7) | 83.3 (35.9 to 99.6) | 42.9 (9.9 to 81.6) | 33.3 (0.8 to 90.6) | — | — | 66.7 (9.4 to 99.2) |
| Recovery- Respiratory | 37.5 (8.5 to 75.5) | 81.8 (48.2 to 97.7) | 83.3 (35.9 to 99.6) | 42.9 (9.9 to 81.6) | 33.3 (0.8 to 90.6) | — | — | 66.7 (9.4 to 99.2) |
| ≥ 2-point Improvement from Baseline- Behavior | 0 (0 to 84.2) | 33.3 (0.8 to 90.6) | 100 (47.8 to 100) | 66.7 (22.3 to 95.7) | 0 (0 to 84.2) | — | — | 50 (1.3 to 98.7) |
| ≥ 1-point Improvement from Baseline- Behavior | 40 (5.3 to 85.3) | 66.7 (22.3 to 95.7) | 100 (59 to 100) | 66.7 (29.9 to 92.5) | 66.7 (9.4 to 99.2) | — | — | 33.3 (0.8 to 90.6) |
| Recovery- Behavior | 40 (5.3 to 85.3) | 66.7 (22.3 to 95.7) | 100 (59 to 100) | 55.6 (21.2 to 86.3) | 33.3 (0.8 to 90.6) | — | — | 33 (0.8 to 90.6) |
| ≥ 2-point Improvement from Baseline- Cardiovascular | 0 (0 to 84.2) | 66.7 (9.4 to 99.2) | 100 (15.8 to 100) | 100 (15.8 to 100) | — | — | — | — |
| ≥ 1-point Improvement from Baseline- Cardiovascular | 33.3 (0.8 to 90.6) | 80 (28.4 to 99.5) | 100 (47.8 to 100) | 66.7 (9.4 to 99.2) | 50 (1.3 to 98.7) | — | — | 66.7 (9.4 to 99.2) |
| Recovery- Cardiovascular | 0 (0 to 70.8) | 80 (28.4 to 99.5) | 100 (47.8 to 100) | 33.3 (0.8 to 90.6) | 50 (1.3 to 98.7) | — | — | 66.7 (9.4 to 99.2) |
Plasma concentrations were drawn as follows: (1) for Cohorts 1-4 and 8 on Day 2 and Day 3, with Day 5 as optional; (2) for Cohorts 5-7 on Day 2 or Day 3.
| ug/mL | Remdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kg | RDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kg | RDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kg | RDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kg | RDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kg | RDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kg | RDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kg | RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg |
|---|---|---|---|---|---|---|---|---|
| Day 2, End of Infusion | 217.7 ± 262.32 | 173.0 ± 119.06 | 187.8 ± 75.89 | 138.3 ± 104.06 | NA ± NA | — | — | 156.6 ± 57.21 |
| Day 2, 4 hours post infusion | 110.1 ± 270.72 | 24.3 ± 23.90 | 14.2 ± 15.03 | 36.2 ± 32.75 | NA ± NA | — | — | 16.2 ± 8.31 |
| Day 3, Pre-Infusion | 78.5 ± 209.65 | NA ± NA | NA ± NA | NA ± NA | NA ± NA | — | — | NA ± NA |
| Day 3, 2 hours post infusion | 90.1 ± 221.54 | 47.5 ± 52.62 | 47.4 ± 38.99 | 58.2 ± 25.89 | 61.0 ± 79.20 | — | — | 48.0 ± 50.41 |
| Day 5, Middle of Infusion | 229.0 ± 221.14 | 105.5 ± 72.05 | 156.3 ± 23.12 | 118.2 ± 121.22 | — | — | — | 184.2 ± 131.82 |
| Day 5, 6 Hours post infusion | 141.2 ± 261.96 | 6.6 ± 3.15 | NA ± NA | 12.4 ± 9.89 | — | — | — | NA ± NA |
Participants who received at least one concomitant non-study COVID-19 medication from the first day of RDV treatment through the 30-day Follow-up visit or early withdrawal are reported.
| percentage of participants | Remdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kg | RDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kg | RDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kg | RDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kg | RDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kg | RDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kg | RDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kg | RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Concomitant Use of Medications Other Than RDV for Treatment of COVID-19 | 100.0 | 100.0 | 83.3 | 83.3 | 66.7 | — | — | 100.0 |
Collected over All-Cause Mortality: First dose date up to approximately 8 weeks Adverse events: From first dose date (Day 1) up to follow-up assessment (maximum duration: 30 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Remdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kg | 2/12 (16.7%) | 5/12 (41.7%) | 11/12 (91.7%) |
| RDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kg | 1/12 (8.3%) | 2/12 (16.7%) | 7/12 (58.3%) |
| RDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kg | 0/12 (0%) | 0/12 (0%) | 9/12 (75%) |
| RDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kg. | 0/12 (0%) | 3/12 (25%) | 7/12 (58.3%) |
| RDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kg | 0/4 (0%) | 1/3 (33.3%) | 2/3 (66.7%) |
| RDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kg | — | — | — |
| RDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kg | — | — | — |
| RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg | 1/5 (20%) | 1/5 (20%) | 4/5 (80%) |
| Event | Remdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kg | RDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kg | RDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kg | RDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kg. | RDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kg | RDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kg | RDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kg | RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg |
|---|---|---|---|---|---|---|---|---|
| Cardiopulmonary failureCardiac disorders | 0/12 | 0/12 | 0/12 | 0/12 | 1/3 | — | — | 0/5 |
| AcidosisMetabolism and nutrition disorders | 0/12 | 0/12 | 0/12 | 0/12 | 1/3 | — | — | 0/5 |
| SeizureNervous system disorders | 0/12 | 0/12 | 0/12 | 0/12 | 1/3 | — | — | 0/5 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 0/12 | 0/12 | 0/12 | 0/12 | 1/3 | — | — | 0/5 |
| Cardiac failureCardiac disorders | 0/12 | 0/12 | 0/12 | 0/12 | 0/3 | — | — | 1/5 |
| Gastrointestinal necrosisGastrointestinal disorders | 0/12 | 0/12 | 0/12 | 0/12 | 0/3 | — | — | 1/5 |
| PneumoperitoneumGastrointestinal disorders | 0/12 | 0/12 | 0/12 | 0/12 | 0/3 | — | — | 1/5 |
| Multiple organ dysfunction syndromeGeneral disorders | 1/12 | 0/12 | 0/12 | 0/12 | 0/3 | — | — | 1/5 |
| Respiratory distressRespiratory, thoracic and mediastinal disorders | 1/12 | 0/12 | 0/12 | 0/12 | 0/3 | — | — | 1/5 |
| Haemodynamic instabilityVascular disorders | 0/12 | 0/12 | 0/12 | 0/12 | 0/3 | — | — | 1/5 |
| Event | Remdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kg | RDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kg | RDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kg | RDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kg. | RDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kg | RDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kg | RDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kg | RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg |
|---|---|---|---|---|---|---|---|---|
| ConstipationGastrointestinal disorders | 3/12 | 1/12 | 2/12 | 1/12 | 0/3 | — | — | 3/5 |
| HypomagnesaemiaMetabolism and nutrition disorders | 0/12 | 1/12 | 0/12 | 1/12 | 0/3 | — | — | 2/5 |
| AnaemiaBlood and lymphatic system disorders | 1/12 | 1/12 | 0/12 | 1/12 | 1/3 | — | — | 0/5 |
| Infusion site extravasationGeneral disorders | 0/12 | 2/12 | 0/12 | 0/12 | 1/3 | — | — | 0/5 |
| Bacterial disease carrierInfections and infestations | 0/12 | 0/12 | 0/12 | 0/12 | 1/3 | — | — | 0/5 |
| ConjunctivitisInfections and infestations | 0/12 | 0/12 | 0/12 | 0/12 | 1/3 | — | — | 0/5 |
| Chest wall haematomaMusculoskeletal and connective tissue disorders | 0/12 | 0/12 | 0/12 | 0/12 | 1/3 | — | — | 0/5 |
| Acute kidney injuryRenal and urinary disorders | 4/12 | 0/12 | 0/12 | 1/12 | 0/3 | — | — | 1/5 |
| HypertensionVascular disorders | 2/12 | 1/12 | 0/12 | 0/12 | 1/3 | — | — | 1/5 |
| Abdominal painGastrointestinal disorders | 1/12 | 0/12 | 0/12 | 0/12 | 0/3 | — | — | 1/5 |
The Safety Analysis Set included all participants who were enrolled into the study and received at least 1 dose of study drug.
| Age, Customized(Participants) | Remdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kg | RDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kg | RDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kg | RDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kg | RDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kg | RDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kg | RDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kg | RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Newborns (0-27 days) | 0 | 0 | 0 | 0 | 3 | — | — | 0 | 3 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 1 | 12 | 0 | — | — | 0 | 13 |
| Children (2-11 years) | 0 | 8 | 11 | 0 | 0 | — | — | 5 | 24 |
| Adolescents (12-17 years) | 12 | 4 | 0 | 0 | 0 | — | — | 0 | 16 |
| Sex: Female, Male(Participants) | Remdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kg | RDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kg | RDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kg | RDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kg | RDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kg | RDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kg | RDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kg | RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 8 | 7 | 5 | 7 | 1 | — | — | 3 | 31 |
| Male | 4 | 5 | 7 | 5 | 2 | — | — | 2 | 25 |
| Ethnicity (NIH/OMB)(Participants) | Remdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kg | RDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kg | RDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kg | RDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kg | RDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kg | RDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kg | RDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kg | RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 7 | 7 | 3 | 0 | — | — | 3 | 23 |
| Not Hispanic or Latino | 8 | 5 | 5 | 9 | 3 | — | — | 2 | 32 |
| Unknown or Not Reported | 1 | 0 | 0 | 0 | 0 | — | — | 0 | 1 |
| Race (NIH/OMB)(Participants) | Remdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kg | RDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kg | RDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kg | RDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kg | RDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kg | RDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kg | RDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kg | RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | — | — | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | — | — | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | — | — | 0 | 0 |
| Black or African American | 5 | 2 | 4 | 2 | 0 | — | — | 1 | 14 |
| White | 7 | 9 | 6 | 8 | 3 | — | — | 3 | 36 |
| More than one race | 0 | 1 | 2 | 2 | 0 | — | — | 1 | 6 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | — | — | 0 | 0 |
| Region of Enrollment(participants) | Remdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kg | RDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kg | RDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kg | RDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kg | RDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kg | RDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kg | RDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kg | RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg | Total |
|---|---|---|---|---|---|---|---|---|---|
| United States | 9 | 11 | 9 | 9 | 2 | — | — | 3 | 43 |
| United Kingdom | 0 | 0 | 0 | 1 | 0 | — | — | 0 | 1 |
| Italy | 0 | 0 | 0 | 1 | 1 | — | — | 1 | 3 |
| Spain | 3 | 1 | 3 | 1 | 0 | — | — | 1 | 9 |
| Number of Participants With Clinical Status (7-Point Ordinal Scale) Score(Participants) | Remdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kg | RDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kg | RDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kg | RDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kg | RDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kg | RDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kg | RDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kg | RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Score 1 | 0 | 0 | 0 | 0 | 0 | — | — | 0 | 0 |
| Score 2 | 1 | 3 | 3 | 5 | 2 | — | — | 0 | 14 |
| Score 3 | 6 | 4 | 3 | 3 | 1 | — | — | 2 | 19 |
| Score 4 | 2 | 3 | 0 | 3 | 0 | — | — | 2 | 10 |
| Score 5 | 3 | 2 | 6 | 0 | 0 | — | — | 1 | 12 |
| Score 6 | 0 | 0 | 0 | 1 | 0 | — | — | 0 | 1 |
| Score 7 | 0 | 0 | 0 | 0 | 0 | — | — | 0 | 0 |
| Oxygen Support Status(Participants) | Remdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kg | RDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kg | RDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kg | RDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kg | RDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kg | RDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kg | RDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kg | RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg | Total |
|---|---|---|---|---|---|---|---|---|---|
| High Flow Oxygen | 6 | 4 | 3 | 3 | 1 | — | — | 2 | 19 |
| Low Flow Oxygen | 2 | 3 | 0 | 3 | 0 | — | — | 2 | 10 |
| Room Air | 3 | 2 | 6 | 1 | 0 | — | — | 1 | 13 |
| Invasive Mechanical Ventilation Status | 1 | 3 | 3 | 5 | 2 | — | — | 0 | 14 |
| Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Ribonucleic Acid (RNA) Viral Load(log10 copies per mL) | Remdesivir (RDV), Cohort 1: Age 12 to <18 Years and Weight ≥40 kg | RDV, Cohort 2: Age ≥ 28 Days to < 18 Years and Weight ≥ 20 kg to < 40 kg | RDV, Cohort 3: Age ≥ 28 Days to < 18 Years and Weight ≥ 12 kg to < 20 kg | RDV, Cohort 4: Age ≥ 28 Days to < 18 Years and Weight ≥ 3 kg to < 12 kg | RDV,Cohort 5: Age ≥14 - <28 Days of Age, Gestational Age >37 Weeks, and Weight at Baseline ≥2.5 kg | RDV, Cohort 6: Age 0 to < 14 Days of Age, Gestational Age > 37 Weeks, and Birth Weight ≥ 2.5 kg | RDV, Cohort 7: Age 0 to < 56 Days of Age, Gestational Age ≤ 37 Weeks, and Birth Weight ≥ 1.5 kg | RDV, Cohort 8: < 12 Years and Weight ≥ 40 kg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Nasal/oropharyngeal Swabs | 5.35 ± 1.796 | 4.87 ± 2.807 | 3.18 ± 0.967 | 5.41 ± 2.165 | 5.02 ± NA | — | — | 6.20 ± NA | 4.80 ± 1.998 |
| Nasopharyngeal/oropharyngeal Swabs | 5.93 ± 2.172 | 5.37 ± 1.879 | 5.67 ± 2.273 | 5.55 ± 1.854 | 5.99 ± 0.183 | — | — | 6.12 ± 1.628 | 5.78 ± 1.802 |
| Endotracheal Tube Aspirates | 5.36 ± NA | 5.58 ± 3.554 | 6.09 ± 0.840 | 6.68 ± 1.540 | 4.63 ± NA | — | — | — | 5.87 ± 2.180 |
| Rectal/fecal Swabs | 3.30 ± 1.593 | 2.63 ± 0.757 | 2.72 ± 1.034 | 3.84 ± 1.341 | 4.27 ± 1.107 | — | — | 2.75 ± 1.274 | 3.26 ± 1.297 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gileadclinicaltrials.com/transparency-policy#Commitment
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gileadclinicaltrials.com
Ran from Jul 2020 to primary completion in Feb 2023, 30 months.
Results were first posted in Dec 2023, 10 months after primary completion.
Of 73 industry-sponsored phase 2/3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's 30 months is above that.
Counting every sponsor, half of 168 studies reached it within 11 months; a quarter within 5 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Remdesivir